T-1101 is a First-in-Class Hec1/Nek2 inhibitor that disrupts cancer cell cycle division thereby inhibits tumor growth in the body and receives TFDA approval to initiate Phase I clinical study in Taiwan. Patients with advanced tumors have been enrolled into an ongoing open-label, Phase I dose escalation study in Taiwan. Enrollment for this study in Taiwan started in Jan, 2021.

Trial information and inclusion/exclusion criteria are posted on the following website ClinicalTrials.gov: https://clinicaltrials.gov/ct2/show/NCT04685473